LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.840-2.940 for the period, compared to the consensus estimate of 3.000. The company issued revenue guidance of $274.3 million-$278.3 million, compared to the consensus revenue estimate of $279.9 million. LeMaitre Vascular also updated its Q3 2026 guidance to 0.660-0.710 EPS.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on LMAT shares. Barrington Research reaffirmed an “outperform” rating and set a $120.00 target price on shares of LeMaitre Vascular in a research report on Wednesday, June 3rd. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wells Fargo & Company increased their price target on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Trading Up 2.1%

LMAT stock traded up $2.17 during midday trading on Tuesday, hitting $105.78. The stock had a trading volume of 402,218 shares, compared to its average volume of 254,478. The company has a current ratio of 14.32, a quick ratio of 12.20 and a debt-to-equity ratio of 0.42. The firm has a market cap of $2.42 billion, a P/E ratio of 39.03, a price-to-earnings-growth ratio of 2.81 and a beta of 0.52. The business has a fifty day moving average price of $97.27 and a two-hundred day moving average price of $99.90. LeMaitre Vascular has a 1-year low of $79.39 and a 1-year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same period last year, the business posted $0.48 EPS. The business’s revenue was up 11.1% compared to the same quarter last year. On average, sell-side analysts predict that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $111.10, for a total transaction of $560,388.40. Following the sale, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 54,453 shares of company stock worth $5,906,174. 7.40% of the stock is owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Several large investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular in the 2nd quarter valued at about $47,000. Geneos Wealth Management Inc. grew its stake in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 398 shares during the period. Quarry LP grew its stake in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after acquiring an additional 529 shares during the period. Kestra Advisory Services LLC bought a new stake in shares of LeMaitre Vascular during the fourth quarter valued at approximately $68,000. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of LeMaitre Vascular during the fourth quarter valued at approximately $80,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.